Novo-Nordisk A/S
NVODividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| April 8, 2026 | $1.22 | 2026-03-30 | 2026-03-30 |
| August 26, 2025 | $0.58 | 2025-08-18 | 2025-08-18 |
| April 8, 2025 | $1.14 | 2025-03-31 | 2025-03-31 |
| August 26, 2024 | $0.52 | 2024-08-16 | 2024-08-16 |
| April 2, 2024 | $0.93 | 2024-03-22 | 2024-03-25 |
Dividends Summary
- Consistent Payer: Novo-Nordisk A/S has rewarded shareholders with 34 dividend payments over the past 23 years.
- Total Returned Value: Investors who held NVO shares during this period received a total of $32.62 per share in dividend income.
- Latest Payout: The most recent dividend of $1.22/share was paid 101 days ago, on April 8, 2026.
- Dividend Growth: Since 2003, the dividend payout has grown by 132.8%, from $0.52 to $1.22.
Company News
While Eli Lilly's GLP-1 weight-loss drugs (Mounjaro and Zepbound) account for nearly two-thirds of revenues with strong growth, the company is strategically using profits from these drugs to build a diversified pipeline in immunology, oncology, and neuroscience through acquisitions like AtaiBeckley and Ventyx Biosciences. Non-weight-loss drugs ar...
Novo Nordisk's oral Wegovy launch has regained market share in the GLP-1 weight-loss drug market, capturing ~89% of oral weight-loss medication prescriptions in the U.S. However, Eli Lilly's Foundayo has potential advantages including fewer food restrictions and upcoming label expansions for multiple indications. Both companies remain well-positi...
ResearchAndMarkets.com released a comprehensive report analyzing over 1,859 clinical-stage pharmaceutical and biotechnology partnership deals announced since 2020. The report provides detailed financial terms, deal structures, contract documents, and insights into negotiation dynamics for clinical-stage drug development collaborations, serving as...
The global oral obesity therapies market is projected to grow from $4.32 billion in 2026 to $6.32 billion by 2030, with a compound annual growth rate of 9.9%. The market expansion is driven by increasing demand for GLP-1 treatments, combination therapies, personalized metabolic treatments, and telehealth-enabled prescribing. Key opportunities inc...
Eli Lilly's new oral weight loss drug Foundayo is showing concerning early signs with flat prescription growth over five weeks post-launch, significantly trailing Novo Nordisk's oral Wegovy. However, analysts note that Foundayo's slower start may be temporary due to later pharmacy coverage and being a new drug formulation, while Lilly maintains a...
